Citations

Showing 10 of 108083 citations.

1205: A RETROSPECTIVE COHORT ANALYSIS OF CULTURE-POSITIVE AND CULTURE-NEGATIVE SEPSIS
Isha, Shahin , SATASHIA, PARTHKUMAR , Jenkins, Anna , Ball, Colleen T. , Govero, Austin, Hanson, Abby , Cantrell, Warren, Baptista, Aleksandra Murawska , Vizzini, Michael, Sanghavi, Devang , Jenkins, Anna S , Shahin, Isha , Yarrarapu, Siva Naga S. , Gnanapandithan, Karthik

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 601-601

10.1097/01.ccm.0000910556.36674.f6 Get It

Rates of Hypoglycemic and Hyperglycemic Emergencies Among U.S. Adults With Diabetes, 2011–2020
McCoy, Rozalina G. , Galindo, Rodolfo J. , Swarna, Kavya, McCoy, Rozalina Grubina , Galindo, Rodolfo J , Herrin, Jeph , Umpierrez, Guillermo E. , Golden, Sherita Hill , O’Connor, Patrick J.

Mayo Clinic

Diabetes Care | December 15, 2022 | Volume: 46 | Issue: 2 | Pages: e69-e71

10.2337/dc22-1673 | PMID 36520618 Get It

604. Effect of rifabutin in dolutegravir dosing: a case series
Castro, José G. , Boulanger, Catherine, Mendoza, Maria A. , Al‐Shaer, Mohammad H. , Roldan, Giovanni A. , Peloquin, Charles A.

Mayo Clinic

Open Forum Infectious Diseases | December 15, 2022 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/ofid/ofac492.656 Get It

Abstract Background Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV) infected people worldwide. Patients with HIV who have latent TB are 20-30 times more likely to develop active TB. Integrated antiretroviral therapy (ART) early in the treatment for tuberculosis is recommended due to improved morbidity and mortality, however, there can be serious drug interactions. Rifamycins are potent inducers of the CYP3A4 isoform, which can cause sub-therapeutic concentrations of anti-retroviral drugs, among these, rifabutin (RBN) is a less potent inducer of CYP3A4. Pharmacokinetic (PK) studies done on healthy adults showed that rifampin decreased dolutegravir (DTG) concentrations by more than 50 % whereas RBN decreased it by 30%. RBN has been preferred given that its favorable pharmacokinetic and toxicity profile. Currently there are no studies examining the use of RBN and DTG in co-infected persons. This is a case series of 4 co-infected patients receiving both agents who underwent PK analysis. Methods Retrospective analysis of patients in the respiratory care unit (RCU) at Jackson Memorial Hospital in Miami. We included adult patients, admitted to the RCU, with a concomitant diagnosis of HIV and active TB disease who received DTG and RBN, and for which DTG and RBN plasma concentrations were measured for therapeutic drug monitoring (TDM). A non-compartmental analysis was performed and the area under the concentration-time curve (AUC) was calculated for DTG and RBN. Results We report 4 patients (Figure 1) that met criteria and underwent PK analysis. All patients with TB who were treated with RBN had low concentrations of DTG, requiring higher doses of DTG (Table 1 & 2). After adjustments based on PK analysis, there was evidence of a favorable response to treatment in 2 patients, with a less than robust in the 2 others. Adequate suppression of viral load could not be determined for 3 of the patients because of the short observation time. Figure 1:Timelines of patients describing admission and HIV and tuberculosis treatment providedDTG, dolutegravir. RFB, rifabutin. VL, viral load. AFB, Acid fast bacilli. LAD, lymphadenopathy. TAF, Tenofovir alafenamide. FTC, Emtricitabine. TDF, Tenofovir Disoproxil Fumarate. INH, Isoniazid. PYZ, Pyrazinamide. BID, twice a day. QD, daily. IRIS, Immune reconstitution inflammatory syndrome. GU, genitourinary. TB, tuberculosis.Table 1:Patients’ pharmacokinetics of DTGAUCX-Y, area under the concentration-time curve from time X to Y hours; AUC0-tau, area under the concentration-time curve from time zero to the end of the dosing interval; DTG, dolutegravir; TDM, therapeutic drug monitoring. a) AUC0-6 was calculated.Table 2:Patients’ pharmacokinetics of RBNAUCX-Y, area under the concentration-time curve from time X to Y hours; AUC0-tau, area under the concentration-time curve from time zero to the end of the dosing interval; RBN, Rifabutin; TDM, therapeutic drug monitoring. a) All RBN doses given every 24 hours, b) RBN value was trace and AUC was not calculated. Conclusion All patients with HIV and TB who were treated with RBN had low concentrations of DTG. This case series demonstrates that for optimal concomitant use of rifabutin and dolutegravir it is highly recommended to use TDM. Prospective clinical studies are needed to further determine the PK interactions between RBN and DTG and virologic response to treatment. Disclosures All Authors: No reported disclosures.
Electrical devices for functional visceral pain
Camilleri, Michael

Mayo Clinic

Neurogastroenterology & Motility | December 15, 2022 | Volume: 35 | Issue: 3 | Pages: No page available

10.1111/nmo.14518 | PMID 36520617 Get It

AbstractSeveral studies have documented correction of dysmotility in several regions of the gastrointestinal tract based on electrical stimulation of extrinsic nerves supplying those regions. In this issue of Neurogastroenterology and Motility, Ma et al. (2023) document the effect of transcutaneous neuromodulation applied by acustimulation at ST36 for ineffective esophageal motility in patients with gastroesophageal reflux disease. In addition to motor effects, there were also significant effects on GERD symptoms, raising the question whether extrinsic electrical nerve stimulation of the gut can reduce symptoms through effects that target sensation. This brief review summarizes evidence regarding the application of electrical acustimulation, transauricular electrical stimulation, and sacral electrical or magnetic stimulation to reduce abdominal or pelvic pain.
1093: ACUTE KIDNEY INJURY AFTER TRIPLE CANNULATION IN EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
Amal, Tanya , Patnaik, Harsha, Guru, Pramod , Bansal, Vikas, Chaudhary, Sanjay

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 542-542

10.1097/01.ccm.0000910100.11835.56 Get It

1087: CONTINUOUS RENAL REPLACEMENT THERAPY AND MORTALITY IN CRITICALLY ILL OBESE ADULTS
Peters, Bradley, Frazee, Erin N. , Peters, Bradley J. , Mara, Kristin C. , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 539-539

10.1097/01.ccm.0000910076.35381.e9 Get It

1086: IMPACT OF THE AKI IN CARE TRANSITIONS (ACT) PROGRAM ON KIDNEY HEALTH KNOWLEDGE AND QUALITY OF LIFE
Schreier, Diana J., Anderson, Brenda J., Meade, Laurie, Tinaglia, Angeliki G. , Andrea, Kattah, Frazee, Erin N. , May, Heather P. , Anderson, Brenda, Rule, Andrew D. , Kashani, Kianoush

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 538-538

10.1097/01.ccm.0000910072.40722.59 Get It

1036: DIGITAL HEALTH STRATEGIES TO SUPPORT CLINICIAN ICU POPULATION MANAGEMENT: A CROSSOVER STUDY
Lipatov, Kirill , Pinevich, Yuliya , Pickering, Brian, Herasevich, Svetlana , Barwise, Amelia , Lindroth, Heidi , Dong, Yue , Herasevich, Vitaly , Pickering, Brian

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 512-512

10.1097/01.ccm.0000909872.67739.e4 Get It

1032: CRITICAL CARE CLINICIAN NEEDS FOR PRIORITIZATION OF CARE IN INTENSIVE CARE UNIT: A QUALITATIVE STUDY
Pinevich, Yuliya , Pickering, Brian, Herasevich, Svetlana , Lindroth, Heidi , Herasevich, Vitaly , Pickering, Brian, Barwise, Amelia

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 510-510

10.1097/01.ccm.0000909856.52081.a2 Get It

356: THERAPEUTIC USE OF BARICITINIB IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Amal, Tanya , Patnaik, Harsha, Garces, Juan Pablo Domecq , Banga, Akshat , Bansal, Vikas , Iqbal, Kinza , Rathore, Sawai Singh , Bhurwal, Abhishek , Kashyap, Rahul , Lal, Amos

Mayo Clinic

Critical Care Medicine | December 15, 2022 | Volume: 51 | Issue: 1 | Pages: 164-164

10.1097/01.ccm.0000907152.30646.d6 Get It